Stay updated on ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC
Sign up to get notified when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.

Latest updates to the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page
- CheckyesterdayChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed; no substantive changes to core content, pricing, or availability.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, as well as the introduction of new drug names such as Eribulin Mesylate and Pembrolizumab. However, several previous entries related to location and drug classifications have been removed.SummaryDifference1%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check44 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC
Enter your email address, and we'll notify you when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.